3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Prostatic Neoplasms
2
Lymphoma
2
Sleep Initiation and Maintenance Disorders
1
Sedentary Behavior
1
Oligodendroglioma
1
Meningioma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Fatigue
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Hydroxyurea
7
Bevacizumab
7
Everolimus
6
lutetium Lu 177 dotatate
4
Magnetic Resonance Spectroscopy
4
pembrolizumab
3
abemaciclib
3
Sunitinib
3
Imatinib Mesylate
3
vistusertib
2
gallium Ga 68 dotatate
2
arginyllysine
2
aldesleukin
2
Whole Body Imaging
2
Specimen Handling
2
Radiotherapy
2
Octreotide
2
Nivolumab
2
Cyclophosphamide
2
Amino Acids
2
90Y-octreotide, DOTA-Tyr(3)-
2
vatalanib
1
tozuleristide
1
sargramostim
1
regorafenib
1
pasireotide
1
neratinib
1
fludarabine phosphate
1
fludarabine
1
dexamethasone acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Meningioma
×
Cognitive Behavioral Therapy
×
Clear all
NCT06439420
2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2
Completed
70 enrolled